Table 1.
Bispecific antibody patents from Chinese applications granted by the United States Patent and Trademark Office [36,37]
| Number | Title | International patent classification | Assignee | Earliest publication date | Patent no. |
|---|---|---|---|---|---|
| 1 | Anti-human ovarian cancer-anti CD3 bsAb | C07K16/30AI A61K39/395AI C07K16/28AI C07K19/00AI C12N15/13AI C12N15/62AI C12N15/63AI C12P21/08AI | Beijing ABT Genetic Engineering Technology Co. Ltd. (Beijing, CN) | 17 November 2005 | US7262276 |
| 2 | Multi-specific FAB fusion proteins and methods of use | A61K39/395 C07K14/705 C07K16/28 C07K16/30 C07K16/46 | Generon (Shanghai, CN) | 20 December 2012 | US8846042 |
| 3 | Bispecific antibody | C07K16/46 C07K16/28 C07K16/32 | YZYBio (Wuhan, CN) | 28 August 2014 | US9079965 US9562110 |
| 4 | Bispecific antibodies that bind EGFR and VEGF | C07K16/22 C07K16/28 C07K16/30 | Bio-Thera Solutions Co. Ltd. (Guangzhou, CN) | 12 February 2015 | US9567403 |
| 5 | Multi-functional antibody polypeptide for cryptic epitope of epidermal growth factor receptor and T cell antigen | A61K39/00 C07K16/28 C07K14/71 | Carsgen Therapeutics Co. Ltd. (Shanghai, CN) | 2 April 2015 | US10023639 |
| 6 | Method for preparing homodimer protein mixture by using charge repulsion effect | C12P21/02 A61K39/395 C07K16/00 A61K39/00 | Alphamab (Suzhou, CN) | 1 October 2015 | US9708389 |
| 7 | Construction and application of bsAb EpCAM×CD3 | C07K16/46 C07K16/28 C07K16/30 C07K16/32 | YZYBio (Wuhan, CN) | 31 March 2016 | US9777073 |
| 8 | Construction and application of bsAb HER2×CD3 | C07K16/28 C07K16/40 C07K16/32 | YZYBio (Wuhan, CN) | 26 May 2016 | US9611325 US10118964 |
| 9 | Fabs-in-tandem immunoglobulin and uses thereof | A61K39/00 A61K39/395 A61K45/06 C07K16/00 C07K16/24 C07K16/28 C07K16/46 | Epimab (Shanghai, CN) | 6 October 2016 | US10266608 US10519251 |
| 10 | Bispecific anti-HER2 antibody | C07K16/32 A61K39/395 A61K39/00 | Mabworks (Beijing, CN) | 29 August 2017 | US9745382 US10377833 |
| 11 | Bispecific multivalent fusion proteins | A61K39/21 A61K38/00 A61K39/00 A61K47/68 A61P31/18 C07K14/73 C07K16/10 | US Dept of health (MD,US) Fudan university (Shanghai, CN) | 3 May 2018 | US10472412 |
| 12 | BsAb-mediated cancer therapy with cytokine-induced killer cell | C07K16/32 C07K16/28 A61P35/00 | YZYBio (Wuhan, CN) | 1 November 2018 | US10556964 |